Skip to content

Insider · CIK 0001787700

Amit Hasija

cfoofficer

Files at MIST (Milestone Pharmaceuticals Inc.). First filing Jan 28, 2026, latest Jan 28, 2026.

In brief

Amit Hasija files SEC Form 4 as CFO at MIST (Milestone Pharmaceuticals Inc.). Since Jan 28, 2026, Amit Hasija has reported 0 open-market buys worth $0 and 1 open-market sell worth $158k, the latest filed on Jan 28, 2026.

A track record needs three past buys with six months of prices behind them; Amit Hasija has 0, so none is measured yet.

The newest scored trade: sold $158k of MIST on Dec 15, 2025, filed Jan 28, 2026, scored 43 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $158k.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $158k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

MIST: Milestone Pharmaceuticals Inc.

MISTOct 9, 2026 · close 0.76

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
43Moderate
MISTsell 5
Milestone Pharmaceuticals Inc.
$158k
70,252 shares
-47%-

Transactions

Every row this insider has filed, 14 in all, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Feb 2, 2026MIST
Milestone Pharmaceuticals Inc.
AGrant or award
Employee Stock Option (right to buy)derivative
+204,000$0.00$0204,000Feb 5, 2026
Feb 2, 2026MIST
Milestone Pharmaceuticals Inc.
AGrant or award
Employee Stock Option (right to buy)derivative
+204,000$0.00$0204,000Feb 4, 2026
Feb 2, 2026MIST
Milestone Pharmaceuticals Inc.
AGrant or award
Restricted Stock Unitderivative
+136,000$0.00$0136,000Feb 4, 2026
Dec 12, 2025MIST
Milestone Pharmaceuticals Inc.
AGrant or award
Common Shares
+100,000--150,000Jan 28, 2026
Dec 15, 2025MIST
Milestone Pharmaceuticals Inc.
SOpen-market sale
Common Shares
-58,007$2.32$135k91,993Jan 28, 2026
Jan 26, 2026MIST
Milestone Pharmaceuticals Inc.
MOption exercise
Common Shares
+20,100--112,093Jan 28, 2026
Jan 26, 2026MIST
Milestone Pharmaceuticals Inc.
SOpen-market sale
Common Shares
-12,245$1.93$24k99,848Jan 28, 2026
Dec 12, 2025MIST
Milestone Pharmaceuticals Inc.
AGrant or award
Employee Stock Option (right to buy)derivative
+100,000$0.00$0100,000Jan 28, 2026
Jan 26, 2026MIST
Milestone Pharmaceuticals Inc.
MOption exercise
Restricted Stock Unitsderivative
-20,100$0.00$060,300Jan 28, 2026
Jul 11, 2025MIST
Milestone Pharmaceuticals Inc.
AGrant or award
Common Shares
+50,000--50,000Jul 15, 2025
Jul 11, 2025MIST
Milestone Pharmaceuticals Inc.
AGrant or award
Series A Common Warrants (right to buy)derivative
+50,000--50,000Jul 15, 2025
Jul 11, 2025MIST
Milestone Pharmaceuticals Inc.
AGrant or award
Series B Common Warrants (right to buy)derivative
+50,000--50,000Jul 15, 2025
Jan 27, 2025MIST
Milestone Pharmaceuticals Inc.
AGrant or award
Employee Stock Option (right to buy)derivative
+120,600$0.00$0120,600Jan 29, 2025
Jan 27, 2025MIST
Milestone Pharmaceuticals Inc.
AGrant or award
Restricted Stock Unitderivative
+80,400$0.00$080,400Jan 29, 2025

Questions about Amit Hasija

Answered from the filings on this page, as of the latest one.

Is Amit Hasija buying or selling?

In the last 12 months Amit Hasija reported 0 open-market buys worth $0 and 1 open-market sell worth $158k on SEC Form 4; the latest was sold $158k of MIST on Dec 15, 2025. Grants, option exercises and tax withholding are not counted.

How did Amit Hasija's past buys perform?

Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Amit Hasija has 0.

Where does Amit Hasija file Form 4?

Amit Hasija has filed Form 4 at MIST (Milestone Pharmaceuticals Inc.) as CFO & EVP of Corp. Development. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Amit Hasija: insider trades and track record | InsiderTell